trastuzumab + pertuzumab
Clinical- Indications
- HER2-positive breast cancer
Company intelligence / Profile preview
MEDSIR specializes in designing, developing, and managing independent and collaborative oncology clinical research. Since its founding in Barcelona in 2012 by leading oncologists Javier Cortés, Antonio Llombart, and Maria Campos, the company has supported over sixty-five investigator-driven clinical trials at more than two hundred sites across fourteen countries. Their work has led to over fifty peer-reviewed publications—many in top-tier journals—and presentations at major international congresses. The company’s model emphasizes scientific rigor, operational agility, global collaboration with more than six hundred researchers worldwide, and efficient translation of innovative concepts into impactful patient-focused data.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MEDSIR.